The DOI matches its Crossref record; 125 of the 125 references it cites were found in a registry or an index.
Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling
Open accessAbstract
The successful treatment of certain autoimmune conditions with the humanized anti-IL-6 receptor (IL-6R) antibody tocilizumab has emphasized the clinical importance of cytokines that signal through the β-receptor subunit glycoprotein 130 (gp130).In this Review, we explore how gp130 signaling controls disease progression and examine why IL-6 has a special role among these cytokines as an inflammatory regulator.Attention will be given to the role of the soluble IL-6R, and we will provide a perspective into the clinical blockade of IL-6 activity in autoimmunity, inflammation, and cancer.Conflict of interest: Stefan Rose-John is an inventor on the patent describing the function of sgp130Fc.He is also a shareholder of the CONARIS Research Institute (Kiel, Germany), which is commercially developing sgp130Fc as a therapy for inflammatory diseases.Simon A. Jones has a consultancy agreement with Roche Pharmaceuticals and advises research relating to the clinical introduction of Actemra/RoActemra.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
STATs in cancer inflammation and immunity: a leading role for STAT3
Yu, H., Pardoll, D., & Jove, R. (2009) · Nature reviews. Cancer · doi:10.1038/nrc2734 · Cited by 4,383
Veldhoen, M., Hocking, R. J., Atkins, C. J., Locksley, R. M., & Stockinger, B. (2006) · Immunity · doi:10.1016/j.immuni.2006.01.001 · Cited by 3,605
Principles of interleukin (IL)-6-type cytokine signalling and its regulation
HEINRICH, P. C., BEHRMANN, I., HAAN, S., HERMANNS, H. M., MÜLLER-NEWEN, G., & SCHAPER, F. (2003) · Biochemical Journal · doi:10.1042/bj20030407 · Cited by 3,272 · cited 7×
“IL-6 is traditionally considered a regulator of acute phase inflammatory responses and a lymphocyte stimulatory factor (14).”
BackgroundInfluentialCytokines in the pathogenesis of rheumatoid arthritis
McInnes, I. B., & Schett, G. (2007) · Nature Reviews Immunology · doi:10.1038/nri2094 · Cited by 2,529
Grivennikov, S., Karin, E., Terzic, J., Mucida, D., Yu, G.-Y., Vallabhapurapu, S., Scheller, J., Rose-John, S., Cheroutre, H., Eckmann, L., et al. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.01.001 · Cited by 2,155
Self-citationGender Disparity in Liver Cancer Due to Sex Differences in MyD88-Dependent IL-6 Production
Naugler, W. E., Sakurai, T., Kim, S., Maeda, S., Kim, K., Elsharkawy, A. M., & Karin, M. (2007) · Science · doi:10.1126/science.1140485 · Cited by 1,955
Impaired immune and acute-phase responses in interleukin-6-deficient mice
Kopf, M., Baumann, H., Freer, G., Freudenberg, M., Lamers, M., Kishimoto, T., Zinkernagel, R., Bluethmann, H., & Köhler, G. (1994) · Nature · doi:10.1038/368339a0 · Cited by 1,768 · cited 2×
“In particular, IL-6–deficient (IL-6KO) mice are viable but show numerous immunological defects (15).”
BackgroundAtreya, R., Mudter, J., Finotto, S., Müllberg, J., Jostock, T., Wirtz, S., Schütz, M., Bartsch, B., Holtmann, M., Becker, C., et al. (2000) · Nature Medicine · doi:10.1038/75068 · Cited by 1,293
Self-citationGenome-wide association study meta-analysis identifies seven new rheumatoid arthritis risk loci
BIRAC Consortium, Stahl, E. A., YEAR Consortium, Raychaudhuri, S., Remmers, E. F., Xie, G., Eyre, S., Thomson, B. P., Li, Y., Kurreeman, F. A. S., et al. (2010) · Nature Genetics · doi:10.1038/ng.582 · Cited by 1,253
Waage, A., Brandtzaeg, P., Halstensen, A., Kierulf, P., & Espevik, T. (1989) · The Journal of experimental medicine · doi:10.1084/jem.169.1.333 · Cited by 1,173
Dangerous liaisons: STAT3 and NF-κB collaboration and crosstalk in cancer
Grivennikov, S. I., & Karin, M. (2010) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2009.11.005 · Cited by 1,160
Emery, P., Keystone, E., Tony, H. P., Cantagrel, A., van Vollenhoven, R., Sanchez, A., Alecock, E., Lee, J., & Kremer, J. (2008) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2008.092932 · Cited by 1,104
Stumhofer, J. S., Laurence, A., Wilson, E. H., Huang, E., Tato, C. M., Johnson, L. M., Villarino, A. V., Huang, Q., Yoshimura, A., Sehy, D., et al. (2006) · Nature Immunology · doi:10.1038/ni1376 · Cited by 955
Bollrath, J., Phesse, T. J., von Burstin, V. A., Putoczki, T., Bennecke, M., Bateman, T., Nebelsiek, T., Lundgren-May, T., Canli, Ö., Schwitalla, S., et al. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.01.002 · Cited by 946 · cited 2×
“For instance, in murine models of inflammation-induced colorectal cancer, STAT3-dependent tumorigenesis has been associated with both the local secretion of IL-6 (102, 103) and regulation of IL-6 trans-signaling (80, 83) within the tumor microenvironment.”
BackgroundLesina, M., Kurkowski, M. U., Ludes, K., Rose-John, S., Treiber, M., Klöppel, G., Yoshimura, A., Reindl, W., Sipos, B., Akira, S., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.03.009 · Cited by 862
Self-citationNew IL-12-family members: IL-23 and IL-27, cytokines with divergent functions
Hunter, C. A. (2005) · Nature Reviews Immunology · doi:10.1038/nri1648 · Cited by 852
IL-6: From its discovery to clinical applications
Kishimoto, T. (2010) · International Immunology · doi:10.1093/intimm/dxq030 · Cited by 846
Tilg, H., Trehu, E., Atkins, M., Dinarello, C., & Mier, J. (1994) · Blood · doi:10.1182/blood.v83.1.113.113 · Cited by 817
Hurst, S. M., Wilkinson, T. S., McLoughlin, R. M., Jones, S., Horiuchi, S., Yamamoto, N., Rose-John, S., Fuller, G. M., Topley, N., & Jones, S. A. (2001) · Immunity · doi:10.1016/s1074-7613(01)00151-0 · Cited by 811
Self-citationNishimoto, N., Terao, K., Mima, T., Nakahara, H., Takagi, N., & Kakehi, T. (2008) · Blood · doi:10.1182/blood-2008-05-155846 · Cited by 795
Yokota, S., Imagawa, T., Mori, M., Miyamae, T., Aihara, Y., Takei, S., Iwata, N., Umebayashi, H., Murata, T., Miyoshi, M., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60454-7 · Cited by 789
Soluble receptors for cytokines and growth factors: generation and biological function
Rose-John, S., & Heinrich, P. C. (1994) · Biochemical Journal · doi:10.1042/bj3000281 · Cited by 775
Self-citationInterleukins 27 and 6 induce STAT3-mediated T cell production of interleukin 10
Stumhofer, J. S., Silver, J. S., Laurence, A., Porrett, P. M., Harris, T. H., Turka, L. A., Ernst, M., Saris, C. J. M., O'Shea, J. J., & Hunter, C. A. (2007) · Nature Immunology · doi:10.1038/ni1537 · Cited by 775
Directing Transition from Innate to Acquired Immunity: Defining a Role for IL-6
Jones, S. A. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.6.3463 · Cited by 771
Self-citationBromberg, J. (2002) · Journal of Clinical Investigation · doi:10.1172/jci15617 · Cited by 770
Understanding the IL-23–IL-17 immune pathway
McKenzie, B. S., Kastelein, R. A., & Cua, D. J. (2006) · Trends in Immunology · doi:10.1016/j.it.2005.10.003 · Cited by 766
Humanized anti–interleukin-6 receptor antibody treatment of multicentric Castleman disease
Nishimoto, N., Kanakura, Y., Aozasa, K., Johkoh, T., Nakamura, M., Nakano, S., Nakano, N., Ikeda, Y., Sasaki, T., Nishioka, K., et al. (2005) · Blood · doi:10.1182/blood-2004-12-4602 · Cited by 754
TGF-β Suppresses Tumor Progression in Colon Cancer by Inhibition of IL-6 trans-Signaling
Becker, C., Fantini, M. C., Schramm, C., Lehr, H. A., Wirtz, S., Nikolaev, A., Burg, J., Strand, S., Kiesslich, R., Huber, S., et al. (2004) · Immunity · doi:10.1016/j.immuni.2004.07.020 · Cited by 726
Self-citationWSX-1 and Glycoprotein 130 Constitute a Signal-Transducing Receptor for IL-27
Pflanz, S., Hibbert, L., Mattson, J., Rosales, R., Vaisberg, E., Bazan, J. F., Phillips, J. H., McClanahan, T. K., de Waal Malefyt, R., & Kastelein, R. A. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.4.2225 · Cited by 695
Development of anti-TNF therapy for rheumatoid arthritis
Feldmann, M. (2002) · Nature Reviews Immunology · doi:10.1038/nri802 · Cited by 673
Rose-John, S., Scheller, J., Elson, G., & Jones, S. A. (2006) · Journal of Leukocyte Biology · doi:10.1189/jlb.1105674 · Cited by 647
Self-citationSoluble gp130 is the natural inhibitor of soluble interleukin‐6 receptor transsignaling responses
Jostock, T., Müllberg, J., Özbek, S., Atreya, R., Blinn, G., Voltz, N., Fischer, M., Neurath, M. F., & Rose‐John, S. (2001) · European Journal of Biochemistry · doi:10.1046/j.1432-1327.2001.01867.x · Cited by 641
Self-citationYoshida, K., Taga, T., Saito, M., Suematsu, S., Kumanogoh, A., Tanaka, T., Fujiwara, H., Hirata, M., Yamagami, T., Nakahata, T., et al. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.1.407 · Cited by 635
The soluble interleukin 6 receptor: mechanisms of production and implications in disease
JONES, S. A., HORIUCHI, S., TOPLEY, N., YAMAMOTO, N., & FULLER, G. M. (2001) · The FASEB Journal · doi:10.1096/fj.99-1003rev · Cited by 623
Self-citationInterleukin 6 is required for the development of collagen-induced arthritis
Alonzi, T., Fattori, E., Lazzaro, D., Costa, P., Probert, L., Kollias, G., De Benedetti, F., Poli, V., & Ciliberto, G. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.187.4.461 · Cited by 604 · cited 1×
“For example, IL-6KO mice show limited susceptibility to antigen-induced arthritis (24), collagen-induced arthritis (25, 26), experimental autoimmune encephalomyelitis (27), multicentric Castleman disease (28), and pristine-induced plasmacytomas (29).”
BackgroundTNF is a potent anti-inflammatory cytokine in autoimmune-mediated demyelination
Liu, J., Marino, M. W., Wong, G., Grail, D., Dunn, A., Bettadapura, J., Slavin, A. J., Old, L., & Bernard, C. C. A. (1998) · Nature Medicine · doi:10.1038/nm0198-078 · Cited by 550
Kremer, J. M., Bloom, B. J., Breedveld, F. C., Coombs, J. H., Fletcher, M. P., Gruben, D., Krishnaswami, S., Burgos‐Vargas, R., Wilkinson, B., Zerbini, C. A. F., et al. (2009) · Arthritis & Rheumatism · doi:10.1002/art.24567 · Cited by 546
Kotake, S., Sato, K., Kim, K. J., Takahashi, N., Udagawa, N., Nakamura, I., Yamaguchi, A., Kishimoto, T., Suda, T., & Kashiwazaki, S. (1996) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650110113 · Cited by 545
ADAM17: a molecular switch to control inflammation and tissue regeneration
Scheller, J., Chalaris, A., Garbers, C., & Rose-John, S. (2011) · Trends in Immunology · doi:10.1016/j.it.2011.05.005 · Cited by 526
Self-citationFrequent in-frame somatic deletions activate gp130 in inflammatory hepatocellular tumours
Rebouissou, S., Amessou, M., Couchy, G., Poussin, K., Imbeaud, S., Pilati, C., Izard, T., Balabaud, C., Bioulac-Sage, P., & Zucman-Rossi, J. (2009) · Nature · doi:10.1038/nature07475 · Cited by 477 · cited 1×
“For example, in hepatocellular adenoma, somatic mutations coding for constitutively activated gp130 have been detected (107), while elevated IL-6 levels in patients with breast, lung, and hematopoietic tumors correlate with poor clinical outcome (108, 109).”
BackgroundRobb, L., Li, R., Hartley, L., Nandurkar, H. H., Koentgen, F., & Begley, C. G. (1998) · Nature Medicine · doi:10.1038/nm0398-303 · Cited by 468
Soluble cytokine receptors are present in normal human urine.
Novick, D., Engelmann, H., Wallach, D., & Rubinstein, M. (1989) · The Journal of experimental medicine · doi:10.1084/jem.170.4.1409 · Cited by 434
Pennica, D., Shaw, K. J., Swanson, T. A., Moore, M. W., Shelton, D. L., Zioncheck, K. A., Rosenthal, A., Taga, T., Paoni, N. F., & Wood, W. I. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.18.10915 · Cited by 429
IL-6 Regulates Neutrophil Trafficking during Acute Inflammation via STAT3
Fielding, C. A., McLoughlin, R. M., McLeod, L., Colmont, C. S., Najdovska, M., Grail, D., Ernst, M., Jones, S. A., Topley, N., & Jenkins, B. J. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.3.2189 · Cited by 408
Self-citationInterleukin 6 plays a key role in the development of antigen-induced arthritis
Ohshima, S., Saeki, Y., Mima, T., Sasai, M., Nishioka, K., Nomura, S., Kopf, M., Katada, Y., Tanaka, T., Suemura, M., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.14.8222 · Cited by 406 · cited 1×
“For example, IL-6KO mice show limited susceptibility to antigen-induced arthritis (24), collagen-induced arthritis (25, 26), experimental autoimmune encephalomyelitis (27), multicentric Castleman disease (28), and pristine-induced plasmacytomas (29).”
BackgroundWelte, T., Zhang, S. S. M., Wang, T., Zhang, Z., Hesslein, D. G. T., Yin, Z., Kano, A., Iwamoto, Y., Li, E., Craft, J. E., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0237137100 · Cited by 381
DeChiara, T. M., Vejsada, R., Poueymirou, W. T., Acheson, A., Suri, C., Conover, J. C., Friedman, B., McClain, J., Pan, L., Stahl, N., et al. (1995) · Cell · doi:10.1016/0092-8674(95)90172-8 · Cited by 379
Interleukin‐6 and its receptor in cancer: Implications for Translational Therapeutics
Hong, D. S., Angelo, L. S., & Kurzrock, R. (2007) · Cancer · doi:10.1002/cncr.22999 · Cited by 370
Escary, J.-L., Perreau, J., Duménil, D., Ezine, S., & Brûlet, P. (1993) · Nature · doi:10.1038/363361a0 · Cited by 364
The IL-6/sIL-6R complex as a novel target for therapeutic approaches
Rose-John, S., Waetzig, G. H., Scheller, J., Grötzinger, J., & Seegert, D. (2007) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.11.5.613 · Cited by 360
Self-citationErnst, M., Najdovska, M., Grail, D., Lundgren-May, T., Buchert, M., Tye, H., Matthews, V. B., Armes, J., Bhathal, P. S., Hughes, N. R., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci34944 · Cited by 350
Roles of STAT3 defined by tissue-specific gene targeting
Akira, S. (2000) · Oncogene · doi:10.1038/sj.onc.1203478 · Cited by 344
Interleukin-6-deficient mice develop hepatic inflammation and systemic insulin resistance
Matthews, V. B., Allen, T. L., Risis, S., Chan, M. H. S., Henstridge, D. C., Watson, N., Zaffino, L. A., Babb, J. R., Boon, J., Meikle, P. J., et al. (2010) · Diabetologia · doi:10.1007/s00125-010-1865-y · Cited by 334
Doganci, A., Eigenbrod, T., Krug, N., De Sanctis, G. T., Hausding, M., Erpenbeck, V. J., Haddad, E.-B., Schmitt, E., Bopp, T., Kallen, K.-J., et al. (2005) · Journal of Clinical Investigation · doi:10.1172/jci22433 · Cited by 333
Self-citationCritical Roles for Interleukin 1 and Tumor Necrosis Factor α in Antibody-induced Arthritis
Ji, H., Pettit, A., Ohmura, K., Ortiz-Lopez, A., Duchatelle, V., Degott, C., Gravallese, E., Mathis, D., & Benoist, C. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20020439 · Cited by 332
Human soluble IL-6 receptor: its detection and enhanced release by HIV infection
Honda, M., Yamamoto, S., Cheng, M., Yasukawa, K., Suzuki, H., Saito, T., Osugi, Y., Tokunaga, T., & Kishimoto, T. (1992) · The Journal of Immunology · doi:10.4049/jimmunol.148.7.2175 · Cited by 331
Chalaris, A., Rabe, B., Paliga, K., Lange, H., Laskay, T., Fielding, C. A., Jones, S. A., Rose-John, S., & Scheller, J. (2007) · Blood · doi:10.1182/blood-2007-01-067918 · Cited by 329
Self-citationBachelot, T., Ray-Coquard, I., Menetrier-Caux, C., Rastkha, M., Duc, A., & Blay, J.-Y. (2003) · British Journal of Cancer · doi:10.1038/sj.bjc.6600956 · Cited by 317
Jenkins, B. J., Grail, D., Nheu, T., Najdovska, M., Wang, B., Waring, P., Inglese, M., McLoughlin, R. M., Jones, S. A., Topley, N., et al. (2005) · Nature Medicine · doi:10.1038/nm1282 · Cited by 308
Self-citationDoganci, A., Eigenbrod, T., Krug, N., De Sanctis, G. T., Hausding, M., Erpenbeck, V. J., Haddad, E.-B., Schmitt, E., Bopp, T., Kallen, K.-J., et al. (2005) · Journal of Clinical Investigation · doi:10.1172/jci200522433 · Cited by 304
Self-citationPeters, M., Jacobs, S., Ehlers, M., Vollmer, P., Müllberg, J., Wolf, E., Brem, G., Meyer zum Büschenfelde, K. H., & Rose-John, S. (1996) · The Journal of experimental medicine · doi:10.1084/jem.183.4.1399 · Cited by 276
Self-citationReshaping a human antibody to inhibit the interleukin 6-dependent tumor cell growth.
Sato, K., Tsuchiya, M., Saldanha, J. W., Koishihara, Y., Ohsugi, Y., Kishimoto, T., & Bendig, M. M. (1993) · PubMed · Cited by 274
Wong, P. K. K., Quinn, J. M. W., Sims, N. A., van Nieuwenhuijze, A., Campbell, I. K., & Wicks, I. P. (2006) · Arthritis & Rheumatism · doi:10.1002/art.21537 · Cited by 270
Nowell, M. A., Richards, P. J., Horiuchi, S., Yamamoto, N., Rose-John, S., Topley, N., Williams, A. S., & Jones, S. A. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.171.6.3202 · Cited by 268
Self-citationAverting inflammation by targeting the cytokine environment
Kopf, M., Bachmann, M. F., & Marsland, B. J. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd2805 · Cited by 257
CLF associates with CLC to form a functional heteromeric ligand for the CNTF receptor complex
Elson, G. C. A., Lelièvre, E., Guillet, C., Chevalier, S., Plun-Favreau, H., Froger, J., Suard, I., de Coignac, A. B., Delneste, Y., Bonnefoy, J.-Y., et al. (2000) · Nature Neuroscience · doi:10.1038/78765 · Cited by 252
Targeting TACE-dependent EGFR ligand shedding in breast cancer
Kenny, P. A., & Bissell, M. J. (2007) · Journal of Clinical Investigation · doi:10.1172/jci29518 · Cited by 252
Review: IL-6 Transsignaling: The In Vivo Consequences
Jones, S. A., Richards, P. J., Scheller, J., & Rose-John, S. (2005) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2005.25.241 · Cited by 251
Self-citationDifferences in Wound Healing in Mice with Deficiency of IL-6 versus IL-6 Receptor
McFarland-Mancini, M. M., Funk, H. M., Paluch, A. M., Zhou, M., Giridhar, P. V., Mercer, C. A., Kozma, S. C., & Drew, A. F. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0901929 · Cited by 249
Ups and downs: The STAT1:STAT3 seesaw of Interferon and gp130 receptor signalling
Regis, G., Pensa, S., Boselli, D., Novelli, F., & Poli, V. (2008) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2008.06.004 · Cited by 236
Wunderlich, F. T., Ströhle, P., Könner, A. C., Gruber, S., Tovar, S., Brönneke, H. S., Juntti-Berggren, L., Li, L.-S., van Rooijen, N., Libert, C., et al. (2010) · Cell Metabolism · doi:10.1016/j.cmet.2010.06.011 · Cited by 229 · cited 2×
“However, this cytokine also controls homeostatic functions, including regulation of glucose metabolism (35, 46) and the hypothalamic-pituitary-adrenal axis (47).”
BackgroundDominitzki, S., Fantini, M. C., Neufert, C., Nikolaev, A., Galle, P. R., Scheller, J., Monteleone, G., Rose-John, S., Neurath, M. F., & Becker, C. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.4.2041 · Cited by 227
Self-citationNowell, M. A., Williams, A. S., Carty, S. A., Scheller, J., Hayes, A. J., Jones, G. W., Richards, P. J., Slinn, S., Ernst, M., Jenkins, B. J., et al. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.182.1.613 · Cited by 215
Self-citationMatsumoto, S., Hara, T., Mitsuyama, K., Yamamoto, M., Tsuruta, O., Sata, M., Scheller, J., Rose-John, S., Kado, S.-I., & Takada, T. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0801217 · Cited by 211
Self-citationThe role of transsignalling via the agonistic soluble IL-6 receptor in human diseases
Kallen, K.-J. (2002) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/s0167-4889(02)00325-7 · Cited by 205
Marin, V., Montero-Julian, F. A., Grès, S., Boulay, V., Bongrand, P., Farnarier, C., & Kaplanski, G. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.167.6.3435 · Cited by 204
Modur, V, Li, Y., Zimmerman, G. A., Prescott, S. M., & McIntyre, T. M. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119821 · Cited by 204
Modur, V, Feldhaus, M. J., Weyrich, A. S., Jicha, D. L., Prescott, S. M., Zimmerman, G. A., & McIntyre, T. M. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119508 · Cited by 203
Richards, H. B., Satoh, M., Shaw, M., Libert, C., Poli, V., & Reeves, W. H. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.188.5.985 · Cited by 201
Interleukin-11 regulates the hepatic expression of the same plasma protein genes as interleukin-6.
Baumann, H., & Schendel, P. (1991) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)54940-1 · Cited by 199
C-reactive Protein: A Physiological Activator of Interleukin 6 Receptor Shedding
Jones, S. A., Novick, D., Horiuchi, S., Yamamoto, N., Szalai, A. J., & Fuller, G. M. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.189.3.599 · Cited by 196
Self-citationJones, G. W., McLoughlin, R. M., Hammond, V. J., Parker, C. R., Williams, J. D., Malhotra, R., Scheller, J., Williams, A. S., Rose-John, S., Topley, N., et al. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0901528 · Cited by 189
Self-citationChesnokova, V. (2002) · Endocrinology · doi:10.1210/en.143.5.1571 · Cited by 189
A role for IL-27p28 as an antagonist of gp130-mediated signaling
Stumhofer, J. S., Tait, E. D., III, W. J. Q., Hosken, N., Spudy, B., Goenka, R., Fielding, C. A., O'Hara, A. C., Chen, Y., Jones, M. L., et al. (2010) · Nature Immunology · doi:10.1038/ni.1957 · Cited by 184
Self-citationGearing, D. P., & Cosman, D. (1991) · Cell · doi:10.1016/0092-8674(91)90131-h · Cited by 181
Nowell, M. A., Richards, P. J., Fielding, C. A., Ognjanovic, S., Topley, N., Williams, A. S., Bryant‐Greenwood, G., & Jones, S. A. (2006) · Arthritis & Rheumatism · doi:10.1002/art.21942 · Cited by 178
Self-citationTormo, D., Chęcińska, A., Alonso-Curbelo, D., Pérez-Guijarro, E., Cañón, E., Riveiro-Falkenbach, E., Calvo, T. G., Larribere, L., Megías, D., Mulero, F., et al. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.07.004 · Cited by 178
Barkhausen, T., Tschernig, T., Rosenstiel, P., van Griensven, M., Vonberg, R.-P., Dorsch, M., Mueller-Heine, A., Chalaris, A., Scheller, J., Rose-John, S., et al. (2011) · Critical Care Medicine · doi:10.1097/ccm.0b013e318211ff56 · Cited by 169
Self-citationCutting Edge: Soluble IL-6R Is Produced by IL-6R Ectodomain Shedding in Activated CD4 T Cells
Briso, E. M., Dienz, O., & Rincon, M. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.11.7102 · Cited by 165
Severe inflammatory arthritis and lymphadenopathy in the absence of TNF
Campbell, I. K., O’Donnell, K., Lawlor, K. E., & Wicks, I. P. (2001) · Journal of Clinical Investigation · doi:10.1172/jci12724 · Cited by 161
Nakamura, K., Nonaka, H., Saito, H., Tanaka, M., & Miyajima, A. (2004) · Hepatology · doi:10.1002/hep.20086 · Cited by 157
Interleukin 27 attenuates collagen-induced arthritis
Niedbała, W., Cai, B., Wei, X., Patakas, A., Leung, B. P. L., McInnes, I. B., & Liew, F. Y. (2008) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2007.083360 · Cited by 153
McLoughlin, R. M., Hurst, S. M., Nowell, M. A., Harris, D. A., Horiuchi, S., Morgan, L. W., Wilkinson, T. S., Yamamoto, N., Topley, N., & Jones, S. A. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.9.5676 · Cited by 140
Self-citationThe Jak-STAT pathway in rheumatoid arthritis.
Walker, J. G., & Smith, M. (2005) · PubMed · Cited by 139
Concentrations and origins of soluble interleukin 6 receptor-alpha in serum and synovial fluid.
Desgeorges, A., Gabay, C., Silacci, P., Novick, D., Roux-Lombard, P., Grau, G. E., Dayer, J. M., VISCHER, T. L., & Guerne, P. A. (1997) · PubMed · Cited by 134
STAT3 expression in gastric cancer indicates a poor prognosis
Kim, D., Cha, S., Ahn, D., Kang, H., Kwon, C., Ko, K., Hwang, S., Park, P. J., Rim, K., & Hong, S. (2008) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2008.05671.x · Cited by 125
Stewart, C. L. (1994) · Molecular Reproduction and Development · doi:10.1002/mrd.1080390217 · Cited by 122
Curnow, J., Scheel‐Toellner, D., Jenkinson, W. E., Raza, K., Durrani, O. M., Faint, J., Rauz, S., Wloka, K., Pilling, D., Rose‐John, S., et al. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.8.5290 · Cited by 119
Self-citationThe JAK/STAT pathway in rheumatoid arthritis: Pathogenic or protective?
Ivashkiv, L. B., & Hu, X. (2003) · Arthritis & Rheumatism · doi:10.1002/art.11095 · Cited by 118
Teague, T., Schaefer, B., Hildeman, D. A., Bender, J., Mitchell, T., Kappler, J., & Marrack, P. (2000) · Journal of Experimental Medicine · doi:10.1084/jem.191.6.915 · Cited by 115
de Hooge, A. S. K., van de Loo, F. A. J., Koenders, M. I., Bennink, M. B., Arntz, O. J., Kolbe, T., & van den Berg, W. B. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20302 · Cited by 114
Richards, P. J., Nowell, M. A., Horiuchi, S., McLoughlin, R. M., Fielding, C. A., Grau, S., Yamamoto, N., Ehrmann, M., Rose‐John, S., Williams, A. S., et al. (2006) · Arthritis & Rheumatism · doi:10.1002/art.21818 · Cited by 113
Self-citationDefective development of pristane-oil-induced plasmacytomas in interleukin-6-deficient BALB/c mice.
(1997) · Europe PMC (PubMed Central) · Cited by 111
IL-6 Receptor Independent Stimulation of Human gp130 by Viral IL-6
Müllberg, J., Geib, T., Jostock, T., Hoischen, S. H., Vollmer, P., Voltz, N., Heinz, D. W., Galle, P. R., Klouche, M., & Rose‐John, S. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.9.4672 · Cited by 111
Self-citationLu, Z., Brochier, J., Wijdenes, J., Brailly, H., Bataille, R., & Klein, B. (1992) · European Journal of Immunology · doi:10.1002/eji.1830221110 · Cited by 102
Schiechl, G., Bauer, B., Fuss, I. J., Lang, S. A., Moser, C., Ruemmele, P., Rose‐John, S., Neurath, M. F., Geissler, E. K., Schlitt, H. J., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci42540 · Cited by 102
Self-citationIn vivo effects of the anti–interleukin‐6 receptor inhibitor tocilizumab on the B cell compartment
Roll, P., Muhammad, K., Schumann, M., Kleinert, S., Einsele, H., Dörner, T., & Tony, H. (2011) · Arthritis & Rheumatism · doi:10.1002/art.30242 · Cited by 100
Qu, P., Roberts, J., Yuan, L., Albrecht, M. E., Cummings, O. W., Eble, J. N., Du, H., & Yan, C. (2008) · Lung Cancer · doi:10.1016/j.lungcan.2008.05.025 · Cited by 99
Kalliolias, G. D., Zhao, B., Triantafyllopoulou, A., Park‐Min, K., & Ivashkiv, L. B. (2010) · Arthritis & Rheumatism · doi:10.1002/art.27200 · Cited by 90
An anti‐inflammatory role for interleukin‐11 in established murine collagen‐induced arthritis
Walmsley, BUTLER, MARINOVA‐MUTAFCHIEVA, & Feldmann, M. (1998) · Immunology · doi:10.1046/j.1365-2567.1998.00568.x · Cited by 77
Screpanti, I., Musiani, P., Bellavia, D., Cappelletti, M., Aiello, F. B., Maroder, M., Frati, L., Modesti, A., Gulino, A., & Poli, V. (1996) · The Journal of Experimental Medicine · doi:10.1084/jem.184.4.1561 · Cited by 69
Lissilaa, R., Buatois, V., Magistrelli, G., Williams, A. S., Jones, G. W., Herren, S., Shang, L., Malinge, P., Guilhot, F., Chatel, L., et al. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.1002015 · Cited by 69
Self-citationJones, S. A., Horiuchi, S., Novick, D., Yamamoto, N., & Fuller, G. M. (1998) · European Journal of Immunology · doi:10.1002/(sici)1521-4141(199811)28:11<3514::aid-immu3514>3.0.co;2-t · Cited by 64
Self-citationMarin, V., Montero‐Julian, F. A., Grès, S., Bongrand, P., Farnarier, C., & Kaplanski, G. (2002) · European Journal of Immunology · doi:10.1002/1521-4141(2002010)32:10<2965::aid-immu2965>3.0.co;2-v · Cited by 58
Peters, M. J., Odenthal, M., Schirmacher, P., Blessing, M., Fattori, E., Ciliberto, G., Büschenfelde, K. H. M. Z., & Rose‐John, S. (1997) · The Journal of Immunology · doi:10.4049/jimmunol.159.3.1474 · Cited by 48
Self-citationMoreland, L. W., Gugliotti, R., King, K., Chase, W. F., Weisman, M. H., Greco, T., Fife, R. S., Korn, J. H., Simms, R. W., Tesser, J., et al. (2001) · Arthritis Research & Therapy · doi:10.1186/ar309 · Cited by 48
Sims, N. A. (2008) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2008.08.025 · Cited by 48
STAT3 as a prognostic marker in human gastric cancer
Jackson, C. B., & Giraud, A. S. (2009) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2009.05822.x · Cited by 38
Actemra poised to launch IL-6 inhibitors
Melton, L., & Coombs, A. (2008) · Nature Biotechnology · doi:10.1038/nbt0908-957 · Cited by 37
Inhibiting IL-6 in Human Multiple Myeloma
Klein, B., Lu, Z., Gaillard, J., Harousseau, J., & Bataille, R. (1992) · Current topics in microbiology and immunology · doi:10.1007/978-3-642-77633-5_29 · Cited by 36
Predicting the development of RA in patients with early undifferentiated arthritis
Raza, K., & Filer, A. D. (2009) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2008.08.001 · Cited by 35
Viral IL-6 Blocks Neutrophil Infiltration during Acute Inflammation
Fielding, C. A., McLoughlin, R. M., Colmont, C. S., Kovaleva, M., Harris, D. A., Rose‐John, S., Topley, N., & Jones, S. A. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.6.4024 · Cited by 33
Self-citationEsashi, E., Ito, H., Minehata, K., Saito, S., Morikawa, Y., & Miyajima, A. (2009) · European Journal of Immunology · doi:10.1002/eji.200839149 · Cited by 32
Oncostatin M Receptor-β Signaling Limits Monocytic Cell Recruitment in Acute Inflammation
Hams, E., Colmont, C. S., Dioszeghy, V., Hammond, V. J., Fielding, C. A., Williams, A. S., Tanaka, M., Miyajima, A., Taylor, P. R., Topley, N., et al. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.3.2174 · Cited by 26
Self-citationThe TNF receptor family member CD27 signals to Jun N-terminal kinase via Traf-2
Eugster (1998) · Pure Amsterdam UMC · doi:10.1002/(sici)1521-4141(199807)28:07 · Cited by 2
Cited by
Effective treatment of severe COVID-19 patients with tocilizumab
Xu, X., Han, M., Li, T., Sun, W., Wang, D., Fu, B., Zhou, Y., Zheng, X., Yang, Y., Li, X., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2005615117 · Cited by 2,647
IL-6 as a keystone cytokine in health and disease
Hunter, C. A., & Jones, S. A. (2015) · Nature Immunology · doi:10.1038/ni.3153 · Cited by 2,511
Self-citationRevisiting STAT3 signalling in cancer: new and unexpected biological functions
Yu, H., Lee, H., Herrmann, A., Buettner, R., & Jove, R. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3818 · Cited by 2,137
Cytokine storm and sepsis disease pathogenesis
Chousterman, B. G., Swirski, F. K., & Weber, G. F. (2017) · Seminars in Immunopathology · doi:10.1007/s00281-017-0639-8 · Cited by 1,330
Recent insights into targeting the IL-6 cytokine family in inflammatory diseases and cancer
Jones, S. A., & Jenkins, B. J. (2018) · Nature Reviews Immunology · doi:10.1038/s41577-018-0066-7 · Cited by 1,102
Self-citation
Metadata
- Authors
- Jones, S. A., Scheller, J., & Rose-John, S.
- Venue
- Journal of Clinical Investigation
- Published
- 2011-09-01
- Volume
- 121
- Issue
- 9
- Pages
- 3375-3383
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W1971308765
- Cited by
- 683
- References
- 125
- FWCI
- 25.37
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.